Delving into the Latest Updates on 1-O-methyl-NBD-ceramide-C16 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Chlamydia trachomatis infection

Originator Organization

Robert Koch Institute

Active Organization-

Inactive Organization

Robert Koch Institute

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

ABSTRACTChlamydia trachomatis is a medically important human pathogen causing different diseases, including trachoma, the leading cause of preventable blindness in developing countries, and sexually transmitted infections that can lead to infertility and ectopic pregnancies. There is no vaccine against C. trachomatis at present. Broad-spectrum antibiotics are used as standard therapy to treat the infection but have unwanted side effects, such as inducing persistent or recurring infections and affecting the host microbiome, necessitating the development of novel anti- Chlamydia therapies. Here, we describe the establishment of a robust, fast, and simple plaque assay using liquid overlay medium (LOM) for the identification of anti- Chlamydia compounds. Using the LOM plaque assay, we identified nitrobenzoxadiazole (NBD)-labeled 1- O -methyl-ceramide-C 16 as a compound that efficiently inhibits C. trachomatis replication without affecting the viability of the host cell. Further detailed analyses indicate that 1- O -methyl-NBD-ceramide-C 16 acts outside the inclusion. Thereby, 1- O -methyl-NBD-ceramide-C 16 represents a lead compound for the development of novel anti- Chlamydia drugs and furthermore constitutes an agent to illuminate sphingolipid trafficking pathways in Chlamydia infections.

100 Deals associated with 1-O-methyl-NBD-ceramide-C16

Login to view more data